TY - JOUR
T1 - The association between medication use and health-related quality of life in multimorbid older patients with polypharmacy
AU - Falke, Charlotte
AU - Karapinar, Fatma
AU - Bouvy, Marcel
AU - Emmelot, Marielle
AU - Belitser, Svetlana
AU - Boland, Benoit
AU - O'Mahony, Denis
AU - Murphy, Kevin D.
AU - Haller, Moa
AU - Salari, Paola
AU - Schwenkglenks, Matthias
AU - Rodondi, Nicolas
AU - Egberts, Toine
AU - Knol, Wilma
PY - 2024/12
Y1 - 2024/12
N2 - AimTo explore the association between medication use-related factors and quality of life in older hospitalised patients with polypharmacy.FindingsHyperpolypharmacy, a high anticholinergic and sedative burden, presence of multiple prescribing omissions (based on START criteria), the use of opioids, antibiotics and benzodiazepines, and high medication complexity were associated with a lower quality of life.MessageDue to the association with quality of life, evaluating medication use-related factors, especially medication complexity as a novel factor, is important for hospitalised older patients with (hyper)polypharmacy.PurposeTo explore the association between medication use-related factors and health-related quality of life (HRQoL) in older hospitalised multimorbid patients with polypharmacy.MethodsThis cross-sectional study used the intervention arm data of the OPERAM trial (hospitalised patients >= 70 years with polypharmacy). HRQoL was assessed using the visual analogue scale (EQ-VAS) and the EQ-5D index score of the EuroQol questionnaire (EQ-5D-5L). Lower or higher EQ-VAS/EQ-5D was based on the median of the study population. Medication use-related factors included hyperpolypharmacy (>= 10 medications), anticholinergic and sedative burden, appropriateness of medication (STOPP/START criteria), high-risk medication for hospital (re)admission, medication complexity and adherence. Multivariable logistic regression analysis was used to assess the association between medication use-related factors and HRQoL.ResultsA total of 955 patients were included (mean age 79 years, 46% female, median EQ-VAS of 60, median EQ-5D of 0.60). Opioids use was associated with lower EQ-5D and EQ-VAS (aOR EQ-5D: 2.10; 95% CI 1.34-3.32, EQ-VAS: 1.59; 1.11-2.30). Hyperpolypharmacy (aOR 1.37; 1.05-1.80), antibiotics (aOR 1.64; 1.01-2.68) and high medication complexity (aOR 1.53; 1.10-2.15) were associated with lower EQ-VAS. A high anticholinergic and sedative burden (aOR 1.73; 1.11-2.69), presence of multiple prescribing omissions (aOR 1.94; 1.19-3.17) and benzodiazepine use (aOR 2.01; 1.22-3.35) were associated with lower EQ-5D. Especially in hyperpolypharmacy patients, high anticholinergic and sedative burden and medication complexity were associated with a lower HRQoL.ConclusionSeveral medication use-related factors are significantly associated with a lower HRQoL in hospitalised older patients. Medication complexity is a novel factor, which should be considered when evaluating medication use of older patients with hyperpolypharmacy.
AB - AimTo explore the association between medication use-related factors and quality of life in older hospitalised patients with polypharmacy.FindingsHyperpolypharmacy, a high anticholinergic and sedative burden, presence of multiple prescribing omissions (based on START criteria), the use of opioids, antibiotics and benzodiazepines, and high medication complexity were associated with a lower quality of life.MessageDue to the association with quality of life, evaluating medication use-related factors, especially medication complexity as a novel factor, is important for hospitalised older patients with (hyper)polypharmacy.PurposeTo explore the association between medication use-related factors and health-related quality of life (HRQoL) in older hospitalised multimorbid patients with polypharmacy.MethodsThis cross-sectional study used the intervention arm data of the OPERAM trial (hospitalised patients >= 70 years with polypharmacy). HRQoL was assessed using the visual analogue scale (EQ-VAS) and the EQ-5D index score of the EuroQol questionnaire (EQ-5D-5L). Lower or higher EQ-VAS/EQ-5D was based on the median of the study population. Medication use-related factors included hyperpolypharmacy (>= 10 medications), anticholinergic and sedative burden, appropriateness of medication (STOPP/START criteria), high-risk medication for hospital (re)admission, medication complexity and adherence. Multivariable logistic regression analysis was used to assess the association between medication use-related factors and HRQoL.ResultsA total of 955 patients were included (mean age 79 years, 46% female, median EQ-VAS of 60, median EQ-5D of 0.60). Opioids use was associated with lower EQ-5D and EQ-VAS (aOR EQ-5D: 2.10; 95% CI 1.34-3.32, EQ-VAS: 1.59; 1.11-2.30). Hyperpolypharmacy (aOR 1.37; 1.05-1.80), antibiotics (aOR 1.64; 1.01-2.68) and high medication complexity (aOR 1.53; 1.10-2.15) were associated with lower EQ-VAS. A high anticholinergic and sedative burden (aOR 1.73; 1.11-2.69), presence of multiple prescribing omissions (aOR 1.94; 1.19-3.17) and benzodiazepine use (aOR 2.01; 1.22-3.35) were associated with lower EQ-5D. Especially in hyperpolypharmacy patients, high anticholinergic and sedative burden and medication complexity were associated with a lower HRQoL.ConclusionSeveral medication use-related factors are significantly associated with a lower HRQoL in hospitalised older patients. Medication complexity is a novel factor, which should be considered when evaluating medication use of older patients with hyperpolypharmacy.
KW - HRQoL
KW - Quality of life
KW - Medication use
KW - Medication complexity
KW - Polypharmacy
KW - REGIMEN COMPLEXITY
KW - CHRONIC PAIN
KW - POPULATION
KW - PEOPLE
KW - CARE
KW - OUTCOMES
KW - THERAPY
U2 - 10.1007/s41999-024-01036-4
DO - 10.1007/s41999-024-01036-4
M3 - Article
SN - 1878-7649
VL - 15
SP - 1713
EP - 1723
JO - European Geriatric Medicine
JF - European Geriatric Medicine
IS - 6
ER -